High patient satisfaction with daylight-activated methyl aminolevulinate cream in the treatment of multiple actinic keratoses: A non-interventional study in Australia



Introduction: It is often desirable to treat actinic keratoses (AK) to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. Efficacy and safety of methyl aminolevulinate cream activated by daylight (MAL DL) for AK treatment has previously been demonstrated. The objective of this study was to generate real-life data on the use of MAL DL in treating mild to moderate facial/scalp AK.
Methods: A prospective, multicenter, non-interventional study in Australia in patients receiving a single treatment of MAL DL for mild to moderate AK. Efficacy was assessed 3 months after treatment using a 6-point global improvement scale (1: clear to 6: worse) and satisfaction questionnaires. Adverse events were recorded throughout the study.
Results: Overall, 81 patients were enrolled of mean age 62.7 years, mostly men (76.5%) with skin phototype I (64.2%) or II (35.8%) and a long history of AK (mean duration 16.8 years). Most had multiples lesions (82.7% had ≥11 lesions) of predominantly grade I (75.3%). Physician-assessed efficacy at 3 months was much improved in 88.6% of patients, including 21.5% totally clear. The proportion of patients and physicians satisfied to very satisfied with the MAL DL treatment was 79.7% and 83.3%, respectively. Related AEs were reported in 48.1% of patients, mainly mild erythema (44.4%); only 1 was serious (squamous cell carcinoma).
Conclusions: In clinical practice, the use of MAL DL results in high levels of patient and physician satisfaction reflecting the good efficacy in treating multiple mild non-hyperkeratotic AK of the face and/or scalp.


Dr. Jo-Ann See